Comparative Pharmacology
Head-to-head clinical analysis: RAZADYNE ER versus RIVASTIGMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RAZADYNE ER versus RIVASTIGMINE.
RAZADYNE ER vs RIVASTIGMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversible, competitive acetylcholinesterase inhibitor, increasing acetylcholine concentrations in the synaptic cleft of the central nervous system, particularly enhancing cholinergic neurotransmission in the cerebral cortex and hippocampus.
Reversible acetylcholinesterase inhibitor that enhances cholinergic function by increasing the concentration of acetylcholine at synaptic sites. Also inhibits butyrylcholinesterase.
16 mg orally once daily in the morning; may increase to 24 mg once daily after minimum of 4 weeks; maximum dose 24 mg/day.
1.5 mg orally twice daily initially, titrated by 1.5 mg/dose every 2 weeks to maintenance dose of 3-6 mg twice daily. Alternatively, transdermal patch: 4.6 mg/24h initially, titrate to 9.5 mg/24h after 4 weeks, then 13.3 mg/24h if tolerated.
None Documented
None Documented
Clinical Note
moderateRivastigmine + Dronedarone
"Rivastigmine may increase the bradycardic activities of Dronedarone."
Clinical Note
moderateRivastigmine + Nicotine
"The risk or severity of adverse effects can be increased when Rivastigmine is combined with Nicotine."
Clinical Note
moderateRivastigmine + Amiodarone
"Rivastigmine may increase the bradycardic activities of Amiodarone."
Clinical Note
moderateRivastigmine + Crizotinib
Terminal half-life approximately 7-8 hours; clinical context: supports twice-daily dosing
Terminal half-life ~1.5 h (oral, transdermal); clinical context: due to prolonged binding to acetylcholinesterase (AChE), effective half-life for AChE inhibition is ~10 h; steady state reached in 6-12 weeks.
Renal: 95% as unchanged drug and metabolites; Fecal: 5%
Renal: ~97% total (mostly metabolites, <1% unchanged); fecal: negligible; biliary: minor.
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor
"Rivastigmine may increase the bradycardic activities of Crizotinib."